8-K: Immunome's Varegacestat Shines in Phase 3, Cash Secured

Immunome announced positive Phase 3 RINGSIDE trial results for varegacestat in desmoid tumors, alongside full-year 2025 financials and an extended cash runway into 2028.

Summary

• Immunome reported full-year 2025 financial results and provided a business update on March 3, 2026.
• The global pivotal Phase 3 RINGSIDE trial for varegacestat in patients with progressing desmoid tumors met its primary endpoint, demonstrating an 84% reduction in the risk of disease progression or death (hazard ratio = 0.16, p<0.0001).
• All key secondary endpoints were also met, including an objective response rate of 56% versus 9% with placebo (p<0.0001).
• Varegacestat showed a median best change in tumor volume of -83% compared to +11% with placebo in an exploratory analysis.
• A New Drug Application (NDA) submission to the U.S. FDA for varegacestat is planned for the second quarter of 2026.
• The Phase 1 clinical trial for IM-1021 (ROR1 ADC) is ongoing, with objective responses observed in B-cell lymphoma patients at multiple dose levels, and initial data expected in 2026.
• IND clearance was received for IM-3050 (FAP-targeted radiotherapy), with a Phase 1 study planned to initiate in early 2026.
• Three additional IND submissions for solid tumor-targeted ADC programs (IM-1617, IM-1340, IM-1335) are planned for early, mid, and late-2026, respectively, utilizing Immunome's proprietary HC74 TOP1 inhibitor payload.
• An underwritten public offering in December 2025 raised $460.5 million in gross proceeds, resulting in net proceeds of $432.4 million.
• Cash and cash equivalents totaled $653.5 million as of December 31, 2025, extending the projected cash runway into 2028.
• The net loss for the year ended December 31, 2025, was $212.4 million, an improvement from a net loss of $293.0 million in 2024.
• Research and development expenses increased to $177.3 million in 2025 from $129.5 million in 2024, while in-process research and development expenses decreased to $10.0 million from $152.3 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by successful late-stage clinical trial results for varegacestat, a significant capital raise, and robust pipeline progression, which collectively de-risk the company's near-term future.

Positives

• Positive topline results from the pivotal Phase 3 RINGSIDE trial for varegacestat, meeting its primary endpoint with an 84% reduction in the risk of disease progression or death (HR = 0.16, p<0.0001).
• Varegacestat also met all key secondary endpoints, including an objective response rate of 56% versus 9% with placebo (p<0001).
• Varegacestat demonstrated a median best change in tumor volume of -83% in an exploratory analysis.
• The safety profile of varegacestat was generally well tolerated and consistent with its class.
• Successful underwritten public offering in December 2025 raised $460.5 million in gross proceeds.
• Cash and cash equivalents increased significantly to $653.5 million as of December 31, 2025, from $143.4 million at December 31, 2024.
• Projected cash runway extended into 2028, providing substantial financial stability.
• Objective responses observed in B-cell lymphoma patients in the ongoing Phase 1 trial of IM-1021.
• IND clearance for IM-3050 and plans to initiate a Phase 1 study in early 2026.
• Plans to submit INDs for three differentiated solid tumor ADC programs (IM-1617, IM-1340, IM-1335) in 2026.
• Proprietary HC74 TOP1 inhibitor payload shows promising preclinical data, overcoming multi-drug resistance and exhibiting robust bystander activity.
• Net loss decreased to $212.4 million in 2025 from $293.0 million in 2024.

Negatives

• Reported a net loss of $212.4 million for the year ended December 31, 2025.
• Research and development expenses increased to $177.3 million in 2025 from $129.5 million in 2024.
• General and administrative expenses increased to $43.8 million in 2025 from $33.0 million in 2024.

Risks

• The risk that Immunome will not be able to realize the benefits of its strategic transactions.
• The risk that regulatory approvals for Immunome's programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions.
• The risk that pre-clinical data may not be predictive of clinical data or that early clinical data may not be predictive of later clinical data, regulatory approval or commercial viability.
• The risk of reliance on third-party vendors.
• The risk that Immunome's programs and product candidates fail to achieve their intended endpoints.
• Uncertainties related to Immunome's capital requirements and Immunome's expected cash runway.
• Immunome's ability to grow and advance its pipeline and successfully execute on its business plan.

Future Outlook

Immunome plans to submit a New Drug Application (NDA) for varegacestat in Q2 2026, initiate a Phase 1 study for IM-3050 in early 2026, and submit INDs for three new ADC programs (IM-1617, IM-1340, IM-1335) throughout 2026. Initial data for IM-1021 is expected in 2026. The company projects its current cash position will fund operations into 2028.

Management Comments

• "Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in the second quarter of 2026." Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome.
• "We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch." Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome.
• "We continue to advance our antibody-drug conjugate pipeline, with the Phase 1 study of IM-1021 ongoing. Over the course of 2026, we expect to submit INDs for three differentiated solid tumor ADCs. These programs have substantial potential to benefit cancer patients, and we intend to rapidly advance them." Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome.

Industry Context

StockSavvy.ai notes that Immunome's positive Phase 3 results for varegacestat in desmoid tumors position it strongly in the rare disease oncology market, where effective treatments are highly sought after. The continued advancement of its ADC pipeline, particularly with the novel HC74 payload, aligns with the broader industry trend towards targeted therapies and next-generation ADCs, which are seen as key drivers for future oncology innovation. The extension of its cash runway provides significant operational flexibility in a capital-intensive biotech sector.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial results, extended cash runway, and pipeline advancement, potentially leading to increased share value.
• Patients (Desmoid Tumors): Significant positive impact with a potential new treatment option (varegacestat) showing high efficacy.
• Employees: Positive impact due to company growth, pipeline progress, and financial stability.
• Regulatory Authorities (FDA): Will be reviewing the NDA submission for varegacestat.

Next Steps

• Share additional data from the RINGSIDE trial at an upcoming major medical conference.
• Submit a New Drug Application (NDA) to the U.S. FDA for varegacestat in Q2 2026.
• Present initial data for IM-1021 in 2026.
• Initiate a Phase 1 study for IM-3050 in early 2026.
• Submit INDs for IM-1617 (early 2026), IM-1340 (mid-2026), and IM-1335 (late-2026).
• Continue discovery and lead optimization for additional undisclosed ADCs to support INDs in 2027 and beyond.
• Focus on regulatory, manufacturing, and commercial readiness activities for varegacestat.

Key Dates

Recommendation

The filing presents overwhelmingly positive news, including highly successful Phase 3 clinical trial results for a lead candidate (varegacestat) with a clear path to NDA submission, a substantial capital raise that significantly extends the cash runway, and strong progress across a diverse pipeline of oncology assets. These factors substantially de-risk the company's future and indicate strong growth potential, making it a compelling investment opportunity.

Keywords

Biotechnology, Oncology, Cancer Therapies, Desmoid Tumors, Varegacestat, Antibody-Drug Conjugate, ADC, ROR1 ADC, IM-1021, FAP-targeted radiotherapy, IM-3050, HC74 payload, Clinical Trials, Phase 3, NDA, FDA, Financial Results, Cash Runway, Immunome